Aurobindo Pharma is currently trading at Rs. 206.15, up by 2.40 points or 1.18% from its previous closing of Rs. 203.75 on the BSE.
The scrip opened at Rs. 204.00 and has touched a high and low of Rs. 206.40 and Rs. 202.70 respectively. So far 54432 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 214.80 on 07-Oct-2013 and a 52 week low of Rs. 127.15 on 28-Mar-2013.
Last one week high and low of the scrip stood at Rs. 213.75 and Rs. 202.25 respectively. The current market cap of the company is Rs. 5971.29 crore.
The promoters holding in the company stood at 54.84% while Institutions and Non-Institutions held 31.34% and 13.82% respectively.
Aurobindo Pharma has received US Food & Drug Administration (USFDA) nod for Acyclovir Sodium Injection Generic. Acyclovir is an antiviral drug and is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox.
Earlier in July, the company received final approvals from USFDA to manufacture and market Rizatriptan Benzoate Orally Disintegrating Tablets (ODT) 5mg and 10mg. Rizatriptan Benzoate ODT 5mg and 10mg are the generic equivalent of Merck & Co. Inc’s Maxalt-MLT ODT 5mg and 10mg respectively and indicated for the acute treatment of migraine in adults and in pediatric patients 6 to 17 years of age.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
